DRACPC ID  DRACPC0025

Active Ingredients   Pemetrexed

Description  A synthetic pyrimidine-based antifolate. Pemetrexed binds to and inhibits the enzyme thymidylate synthase (TS), which catalyses the methylation of 2'-deoxyuridine-5'-monophosphate (dUMP) to 2'-deoxythymidine-5'-monophosphate (dTMP), an essential precursor in DNA synthesis.

Synonyms  L-Glutamic Acid, N-(4-(2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl); MTA; Multitargeted Antifolate; Pemfexy; Pemetrexed

Type  Small Molecule

Disease  Non-small cell lung cancer (NSCLC), Mesothelioma

Molecular Formula  C20H21N5O6

Molecular Weight  427.4

Active Sequence  Not available

Sequence Length  Not available

Modification  Not available

Show IUPAC/InChI/SMILES

PubChem CID  135410875

DrugBank Accession Number  DB00642

NCI Thesaurus Code  C61614  

UNII  04Q9AIZ7NO   GSRS

CAS  137281-23-3

Drug indication
    Pemetrexed is indicated for use in patients with non-squamous non-small cell lung cancer (NSCLC), either in combination with pembrolizumab and platinum-based chemotherapy as initial treatment in metastatic disease where no EGFR or ALK genomic tumour aberrations exist, in combination with cisplatin as initial treatment for locally advanced or metastatic disease, as maintenance treatment for locally advanced or metastatic disease that has not progressed following four cycles of platinum-based chemotherapy, and for treatment of recurrent metastatic disease following prior chemotherapy.
Pemetrexed is also indicated in combination with cisplatin for the initial treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery.